Journal Club ft. Nature Publications

Questions discussed in this category

Would you consider combining tovorafenib and trametinib as dual therapy?

3 Answers available

In pediatric patients with low-grade gliomas showing prolonged response or stable disease on tovorafenib, how would you adjust the duration of therapy?

Are there specific safety concerns or long-term risks that should be accounted for when considering drug holidays or overall treatment duration?

2 Answers available

What was the rationale behind using RANO-HGG criteria instead of RAPNO criteria for the primary endpoint in the FIREFLY-1 trial for pLGG?

How will you implement response assessments in patients starting tovorafenib given potential for pseudoprogression vs true progression?

2 Answers available

How has the recent FDA approval of tovorafenib impacted your treatment decisions for pediatric patients with relapsed/refractory low-grade glioma?

Is it merely another option to try or will it become the standard choice for patients experiencing relapsed/refractory disease?

2 Answers available

Papers discussed in this category

Nature medicine, 2023 Nov 17

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

Related Topics